Rare Neuroendocrine Tumors of the Pancreas

  • Shih-Ping Cheng
  • Gerard M. Doherty
Part of the Cancer Treatment and Research book series (CTAR, volume 153)


Neuroendocrine tumors of the pancreas are rare tumors. The annual incidence of pancreatic neuroendocrine tumors is approximately 4–12 cases per million ­population, which is much lower than that reported from autopsy series (about 1%) [1,2]. Neuroendocrine tumors comprise only a minor number of all pancreatic tumors. By incidence, neuroendocrine carcinomas account for 1.3% of all pancreatic cancers. However, in prevalence analyses they represent about 10% of all pancreatic cancers because of the better outcome than exocrine carcinomas [3]. With the development of more sensitive imaging techniques, the number of patients with pancreatic ­neuroendocrine tumors has increased [4,5]. This, however, ­probably does not reflect an actual increase in incidence but rather an improvement in the diagnostic methods.


Neuroendocrine Tumor Vasoactive Intestinal Polypeptide Pancreatic Polypeptide Pancreatic Neuroendocrine Tumor Secretory Diarrhea 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Barakat MT, Meeran K, Bloom SR (2004) Neuroendocrine tumours. Endocr Relat Cancer 11:1–18CrossRefPubMedGoogle Scholar
  2. 2.
    O’Toole D, Salazar R, Falconi M, Kaltsas G, Couvelard A, de Herder WW, Hyrdel R, Nikou G, Krenning E, Vullierme MP, Caplin M, Jensen R, Eriksson B (2006) Rare functioning pancreatic endocrine tumors. Neuroendocrinology 84:189–195CrossRefPubMedGoogle Scholar
  3. 3.
    Yao JC, Eisner MP, Leary C, Dagohoy C, Phan A, Rashid A, Hassan M, Evans DB (2007) Population-based study of islet cell carcinoma. Ann Surg Oncol 14:3492–3500CrossRefPubMedGoogle Scholar
  4. 4.
    Warner RR (2005) Enteroendocrine tumors other than carcinoid: a review of clinically significant advances. Gastroenterology 128:1668–1684CrossRefPubMedGoogle Scholar
  5. 5.
    Jani N, Khalid A, Kaushik N, Brody D, Bauer K, Schoedel K, Ohori NP, Moser AJ, Lee K, McGrath K (2008) EUS-guided FNA diagnosis of pancreatic endocrine tumors: new trends identified. Gastrointest Endosc 67:44–50CrossRefPubMedGoogle Scholar
  6. 6.
    Pearse AG (1969) The cytochemistry and ultrastructure of polypeptide hormone-producing cells of the APUD series and the embryologic, physiologic and pathologic implications of the concept. J Histochem Cytochem 17:303–313PubMedGoogle Scholar
  7. 7.
    Edlund H (2002) Pancreatic organogenesis–developmental mechanisms and implications for therapy. Nat Rev Genet 3:524–532CrossRefPubMedGoogle Scholar
  8. 8.
    Regitnig P, Spuller E, Denk H (2001) Insulinoma of the pancreas with insular-ductular differentiation in its liver metastasis–indication of a common stem-cell origin of the exocrine and endocrine components. Virchows Arch 438:624–628CrossRefPubMedGoogle Scholar
  9. 9.
    Heitz PU, Kasper M, Polak JM, Kloppel G (1982) Pancreatic endocrine tumors. Hum Pathol 13:263–271CrossRefPubMedGoogle Scholar
  10. 10.
    Mansour JC, Chen H (2004) Pancreatic endocrine tumors. J Surg Res 120:139–161CrossRefPubMedGoogle Scholar
  11. 11.
    Heitz PU, Komminoth P, Perren A et al (2004) Tumors of the endocrine pancreas. In: DeLellis RA, Lloyd RV, Heitz PU, Eng C (eds) World Health Organization Classification of tumors. Pathology and genetics of tumors of endocrine organs. IARC Press, Lyon, pp 175–208Google Scholar
  12. 12.
    Oberg K, Kvols L, Caplin M, Delle Fave G, de Herder W, Rindi G, Ruszniewski P, Woltering EA, Wiedenmann B (2004) Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol 15:966–973CrossRefPubMedGoogle Scholar
  13. 13.
    Thompson GB, van Heerden JA, Grant CS, Carney JA, Ilstrup DM (1988) Islet cell carcinomas of the pancreas: a twenty-year experience. Surgery 104:1011–1017PubMedGoogle Scholar
  14. 14.
    Vagefi PA, Razo O, Deshpande V, McGrath DJ, Lauwers GY, Thayer SP, Warshaw AL, Fernandez-Del Castillo C (2007) Evolving patterns in the detection and outcomes of pancreatic neuroendocrine neoplasms: the Massachusetts General Hospital experience from 1977 to 2005. Arch Surg 142:347–354CrossRefPubMedGoogle Scholar
  15. 15.
    Plockinger U, Rindi G, Arnold R, Eriksson B, Krenning EP, de Herder WW, Goede A, Caplin M, Oberg K, Reubi JC, Nilsson O, Delle Fave G, Ruszniewski P, Ahlman H, Wiedenmann B (2004) Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS). Neuroendocrinology 80:394–424CrossRefPubMedGoogle Scholar
  16. 16.
    Ito T, Tanaka M, Sasano H, Osamura YR, Sasaki I, Kimura W, Takano K, Obara T, Ishibashi M, Nakao K, Doi R, Shimatsu A, Nishida T, Komoto I, Hirata Y, Imamura M, Kawabe K, Nakamura K (2007) Preliminary results of a Japanese nationwide survey of neuroendocrine gastrointestinal tumors. J Gastroenterol 42:497–500CrossRefPubMedGoogle Scholar
  17. 17.
    Phan GQ, Yeo CJ, Hruban RH, Littemoe KD, Pitt HA, Cameron JL (1998) Surgical experience with pancreatic and peripancreatic neuroendocrine tumors: Review of 125 patients. J Gastrointest Surg 2:473–482CrossRefPubMedGoogle Scholar
  18. 18.
    Faiss S, Pape UF, Bohmig M, Dorffel Y, Mansmann U, Golder W, Riecken EO, Wiedenmann B (2003) Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors – the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol 21:2689–2696CrossRefPubMedGoogle Scholar
  19. 19.
    Wiedenmann B, Jensen RT, Mignon M, Modlin CI, Skogseid B, Doherty GM, Oberg K (1998) Preoperative diagnosis and surgical management of neuroendocrine gastroenteropancreatic tumors: general recommendations by a consensus workshop. World J Surg 22:309–318CrossRefPubMedGoogle Scholar
  20. 20.
    Falconi M, Plockinger U, Kwekkeboom DJ, Manfredi R, Korner M, Kvols L, Pape UF, Ricke J, Goretzki PE, Wildi S, Steinmuller T, Oberg K, Scoazec JY (2006) Well-differentiated pancreatic nonfunctioning tumors/carcinoma. Neuroendocrinology 84:196–211CrossRefPubMedGoogle Scholar
  21. 21.
    Anlauf M, Garbrecht N, Bauersfeld J, Schmitt A, Henopp T, Komminoth P, Heitz PU, Perren A, Kloppel G (2007) Hereditary neuroendocrine tumors of the gastroenteropancreatic system. Virchows Arch 451(Suppl. 1):S29–S38CrossRefPubMedGoogle Scholar
  22. 22.
    Ghaferi AA, Chojnacki KA, Long WD, Cameron JL, Yeo CJ (2008) Pancreatic VIPomas: subject review and one institutional experience. J Gastrointest Surg 12:382–393CrossRefPubMedGoogle Scholar
  23. 23.
    Verner JV, Morrison AB (1958) Islet cell tumor and a syndrome of refractory watery diarrhea and hypokalemia. Am J Med 25:374–380CrossRefPubMedGoogle Scholar
  24. 24.
    Soga J, Yakuwa Y (1998) Vipoma/diarrheogenic syndrome: a statistical evaluation of 241 reported cases. J Exp Clin Cancer Res 17:389–400PubMedGoogle Scholar
  25. 25.
    Kraenzlin ME, Ch’ng JL, Wood SM, Carr DH, Bloom SR (1985) Long-term treatment of a VIPoma with somatostatin analogue resulting in remission of symptoms and possible shrinkage of metastases. Gastroenterology 88:185–187PubMedGoogle Scholar
  26. 26.
    Fanelli CG, Porcellati F, Rossetti P, Bolli GB (2006) Glucagon: the effects of its excess and deficiency on insulin action. Nutr Metab Cardiovasc Dis 16(Suppl. 1):S28–S34CrossRefPubMedGoogle Scholar
  27. 27.
    Mallinson CN, Bloom SR, Warin AP, Salmon PR, Cox B (1974) A glucagonoma syndrome. Lancet 2:1–5CrossRefPubMedGoogle Scholar
  28. 28.
    Chastain MA (2001) The glucagonoma syndrome: a review of its features and discussion of new perspectives. Am J Med Sci 321:306–320CrossRefPubMedGoogle Scholar
  29. 29.
    Almdal TP, Heindorff H, Bardram L, Vilstrup H (1990) Increased amino acid clearance and urea synthesis in a patient with glucagonoma. Gut 31:946–948CrossRefPubMedGoogle Scholar
  30. 30.
    Stacpoole PW (1981) The glucagonoma syndrome: clinical features, diagnosis, and treatment. Endocr Rev 2:347–361CrossRefPubMedGoogle Scholar
  31. 31.
    Haga Y, Yanagi H, Urata J, Inada M, Shimada S, Nitahata N, Tanimura M (1995) Early detection of pancreatic glucagonoma. Am J Gastroenterol 90:2216–2223PubMedGoogle Scholar
  32. 32.
    Wermers RA, Fatourechi V, Wynne AG, Kvols LK, Lloyd RV (1996) The glucagonoma syndrome. Clinical and pathologic features in 21 patients. Medicine (Baltimore) 75:53–63CrossRefGoogle Scholar
  33. 33.
    Alexander EK, Robinson M, Staniec M, Dluhy RG (2002) Peripheral amino acid and fatty acid infusion for the treatment of necrolytic migratory erythema in the glucagonoma syndrome. Clin Endocrinol (Oxf) 57:827–831CrossRefGoogle Scholar
  34. 34.
    Kindmark H, Sundin A, Granberg D, Dunder K, Skogseid B, Janson ET, Welin S, Oberg K, Eriksson B (2007) Endocrine pancreatic tumors with glucagon hypersecretion: a retrospective study of 23 cases during 20 years. Med Oncol 24:330–337CrossRefPubMedGoogle Scholar
  35. 35.
    Krejs GJ, Orci L, Conlon JM, Ravazzola M, Davis GR, Raskin P, Collins SM, McCarthy DM, Baetens D, Rubenstein A, Aldor TA, Unger RH (1979) Somatostatinoma syndrome. Biochemical, morphologic and clinical features. N Engl J Med 301:285–292CrossRefPubMedGoogle Scholar
  36. 36.
    Mittendorf EA, Shifrin AL, Inabnet WB, Libutti SK, McHenry CR, Demeure MJ (2006) Islet cell tumors. Curr Probl Surg 43:685–765CrossRefPubMedGoogle Scholar
  37. 37.
    House MG, Yeo CJ, Schulick RD (2002) Periampullary pancreatic somatostatinoma. Ann Surg Oncol 9:869–874CrossRefPubMedGoogle Scholar
  38. 38.
    Garbrecht N, Anlauf M, Schmitt A, Henopp T, Sipos B, Raffel A, Eisenberger CF, Knoefel WT, Pavel M, Fottner C, Musholt TJ, Rinke A, Arnold R, Berndt U, Plockinger U, Wiedenmann B, Moch H, Heitz PU, Komminoth P, Perren A, Kloppel G (2008) Somatostatin-producing neuroendocrine tumors of the duodenum and pancreas: incidence, types, biological behavior, association with inherited syndromes, and functional activity. Endocr Relat Cancer 15:229–241CrossRefPubMedGoogle Scholar
  39. 39.
    Tanaka S, Yamasaki S, Matsushita H, Ozawa Y, Kurosaki A, Takeuchi K, Hoshihara Y, Doi T, Watanabe G, Kawaminami K (2000) Duodenal somatostatinoma: a case report and review of 31 cases with special reference to the relationship between tumor size and metastasis. Pathol Int 50:146–152CrossRefPubMedGoogle Scholar
  40. 40.
    Soga J, Yakuwa Y (1999) Somatostatinoma/inhibitory syndrome: a statistical evaluation of 173 reported cases as compared to other pancreatic endocrinomas. J Exp Clin Cancer Res 18:13–22PubMedGoogle Scholar
  41. 41.
    Larsson LI, Hirsch MA, Holst JJ, Ingemansson S, Kuhl C, Jensen SL, Lundqvist G, Rehfeld JF, Schwartz TW (1977) Pancreatic somatostatinoma. Clinical features and physiological implications. Lancet 1:666–668CrossRefPubMedGoogle Scholar
  42. 42.
    Mao C, Shah A, Hanson DJ, Howard JM (1995) Von Recklinghausen’s disease associated with duodenal somatostatinoma: contrast of duodenal versus pancreatic somatostatinomas. J Surg Oncol 59:67–73CrossRefPubMedGoogle Scholar
  43. 43.
    Kouvaraki MA, Solorzano CC, Shapiro SE, Yao JC, Perrier ND, Lee JE, Evans DB (2005) Surgical treatment of non-functioning pancreatic islet cell tumors. J Surg Oncol 89:170–185CrossRefPubMedGoogle Scholar
  44. 44.
    Gullo L, Migliori M, Falconi M, Pederzoli P, Bettini R, Casadei R, Delle Fave G, Corleto VD, Ceccarelli C, Santini D, Tomassetti P (2003) Nonfunctioning pancreatic endocrine tumors: a multicenter clinical study. Am J Gastroenterol 98:2435–2439CrossRefPubMedGoogle Scholar
  45. 45.
    White TJ, Edney JA, Thompson JS, Karrer FW, Moor BJ (1994) Is there a prognostic difference between functional and nonfunctional islet cell tumors? Am J Surg 168:627–630CrossRefPubMedGoogle Scholar
  46. 46.
    Tomassetti P, Campana D, Piscitelli L, Casadei R, Santini D, Nori F, Morselli-Labate AM, Pezzilli R, Corinaldesi R (2005) Endocrine pancreatic tumors: factors correlated with survival. Ann Oncol 16:1806–1810CrossRefPubMedGoogle Scholar
  47. 47.
    Doherty GM (2003) Multiple endocrine neoplasia type 1: duodenopancreatic tumors. Surg Oncol 12:135–143CrossRefPubMedGoogle Scholar
  48. 48.
    Doherty GM (2005) Rare endocrine tumours of the GI tract. Best Pract Res Clin Gastroenterol 19:807–817CrossRefPubMedGoogle Scholar
  49. 49.
    de Herder WW (2007) Biochemistry of neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab 21:33–41CrossRefPubMedGoogle Scholar
  50. 50.
    Nehar D, Lombard-Bohas C, Olivieri S, Claustrat B, Chayvialle JA, Penes MC, Sassolas G, Borson-Chazot F (2004) Interest of Chromogranin A for diagnosis and follow-up of endocrine tumours. Clin Endocrinol (Oxf) 60:644–652CrossRefGoogle Scholar
  51. 51.
    Ricke J, Klose KJ, Mignon M, Oberg K, Wiedenmann B (2001) Standardisation of imaging in neuroendocrine tumours: results of a European delphi process. Eur J Radiol 37:8–17CrossRefPubMedGoogle Scholar
  52. 52.
    Rha SE, Jung SE, Lee KH, Ku YM, Byun JY, Lee JM (2007) CT and MR imaging findings of endocrine tumor of the pancreas according to WHO classification. Eur J Radiol 62:371–377CrossRefPubMedGoogle Scholar
  53. 53.
    Rockall AG, Reznek RH (2007) Imaging of neuroendocrine tumours (CT/MR/US). Best Pract Res Clin Endocrinol Metab 21:43–68CrossRefPubMedGoogle Scholar
  54. 54.
    Rosch T, Lightdale CJ, Botet JF, Boyce GA, Sivak MV Jr, Yasuda K, Heyder N, Palazzo L, Dancygier H, Schusdziarra V et al (1992) Localization of pancreatic endocrine tumors by endoscopic ultrasonography. N Engl J Med 326:1721–1726CrossRefPubMedGoogle Scholar
  55. 55.
    Goldin SB, Bradner MW, Zervos EE, Rosemurgy AS 2nd (2007) Assessment of pancreatic neoplasms: review of biopsy techniques. J Gastrointest Surg 11:783–790CrossRefPubMedGoogle Scholar
  56. 56.
    Intenzo CM, Jabbour S, Lin HC, Miller JL, Kim SM, Capuzzi DM, Mitchell EP (2007) Scintigraphic imaging of body neuroendocrine tumors. Radiographics 27:1355–1369CrossRefPubMedGoogle Scholar
  57. 57.
    Schurr PG, Strate T, Rese K, Kaifi JT, Reichelt U, Petri S, Kleinhans H, Yekebas EF, Izbicki JR (2007) Aggressive surgery improves long-term survival in neuroendocrine pancreatic tumors: an institutional experience. Ann Surg 245:273–281CrossRefPubMedGoogle Scholar
  58. 58.
    Solorzano CC, Lee JE, Pisters PW, Vauthey JN, Ayers GD, Jean ME, Gagel RF, Ajani JA, Wolff RA, Evans DB (2001) Nonfunctioning islet cell carcinoma of the pancreas: survival results in a contemporary series of 163 patients. Surgery 130:1078–1085CrossRefPubMedGoogle Scholar
  59. 59.
    McEntee GP, Nagorney DM, Kvols LK, Moertel CG, Grant CS (1990) Cytoreductive hepatic surgery for neuroendocrine tumors. Surgery 108:1091–1096PubMedGoogle Scholar
  60. 60.
    Norton JA (2006) Surgery for primary pancreatic neuroendocrine tumors. J Gastrointest Surg 10:327–331CrossRefPubMedGoogle Scholar
  61. 61.
    Chamberlain RS, Canes D, Brown KT, Saltz L, Jarnagin W, Fong Y, Blumgart LH (2000) Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg 190:432–445CrossRefPubMedGoogle Scholar
  62. 62.
    Gupta S, Johnson MM, Murthy R, Ahrar K, Wallace MJ, Madoff DC, McRae SE, Hicks ME, Rao S, Vauthey JN, Ajani JA, Yao JC (2005) Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer 104:1590–1602CrossRefPubMedGoogle Scholar
  63. 63.
    Lehnert T (1998) Liver transplantation for metastatic neuroendocrine carcinoma: an analysis of 103 patients. Transplantation 66:1307–1312CrossRefPubMedGoogle Scholar
  64. 64.
    Maton PN, Gardner JD, Jensen RT (1989) Use of long-acting somatostatin analog SMS 201–995 in patients with pancreatic islet cell tumors. Dig Dis Sci 34:28S–39SCrossRefPubMedGoogle Scholar
  65. 65.
    Florio T (2008) Molecular mechanisms of the antiproliferative activity of somatostatin receptors (SSTRs) in neuroendocrine tumors. Front Biosci 13:822–840CrossRefPubMedGoogle Scholar
  66. 66.
    Hejna M, Schmidinger M, Raderer M (2002) The clinical role of somatostatin analogues as antineoplastic agents: much ado about nothing? Ann Oncol 13:653–668CrossRefPubMedGoogle Scholar
  67. 67.
    Toumpanakis C, Meyer T, Caplin ME (2007) Cytotoxic treatment including embolization/chemoembolization for neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab 21:131–144CrossRefPubMedGoogle Scholar
  68. 68.
    Kouvaraki MA, Ajani JA, Hoff P, Wolff R, Evans DB, Lozano R, Yao JC (2004) Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 22:4762–4771CrossRefPubMedGoogle Scholar
  69. 69.
    Moertel CG, Lefkopoulo M, Lipsitz S, Hahn RG, Klaassen D (1992) Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 326:519–523CrossRefPubMedGoogle Scholar
  70. 70.
    Fischer L, Kleeff J, Esposito I, Hinz U, Zimmermann A, Friess H, Buchler MW (2008) Clinical outcome and long-term survival in 118 consecutive patients with neuroendocrine tumours of the pancreas. Br J Surg 95:627–635CrossRefPubMedGoogle Scholar
  71. 71.
    Bettini R, Boninsegna L, Mantovani W, Capelli P, Bassi C, Pederzoli P, Delle Fave GF, Panzuto F, Scarpa A, Falconi M (2008) Prognostic factors at diagnosis and value of WHO classification in a mono-institutional series of 180 non-functioning pancreatic endocrine tumours. Ann Oncol 19:903–908CrossRefPubMedGoogle Scholar
  72. 72.
    Rindi G, Kloppel G, Alhman H, Caplin M, Couvelard A, de Herder WW, Erikssson B, Falchetti A, Falconi M, Komminoth P, Korner M, Lopes JM, McNicol AM, Nilsson O, Perren A, Scarpa A, Scoazec JY, Wiedenmann B (2006) TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 449:395–401CrossRefPubMedGoogle Scholar
  73. 73.
    Touzios JG, Kiely JM, Pitt SC, Rilling WS, Quebbeman EJ, Wilson SD, Pitt HA (2005) Neuroendocrine hepatic metastases: does aggressive management improve survival? Ann Surg 241:776–785CrossRefPubMedGoogle Scholar
  74. 74.
    Ohike N, Morohoshi T (2005) Pathological assessment of pancreatic endocrine tumors for metastatic potential and clinical prognosis. Endocr Pathol 16:33–40CrossRefPubMedGoogle Scholar
  75. 75.
    Lo CY, van Heerden JA, Thompson GB, Grant CS, Soreide JA, Harmsen WS (1996) Islet cell carcinoma of the pancreas. World J Surg 20:878–884CrossRefPubMedGoogle Scholar
  76. 76.
    Hochwald SN, Zee S, Conlon KC, Colleoni R, Louie O, Brennan MF, Klimstra DS (2002) Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. J Clin Oncol 20:2633–2642CrossRefPubMedGoogle Scholar
  77. 77.
    Kazanjian KK, Reber HA, Hines OJ (2006) Resection of pancreatic neuroendocrine tumors: results of 70 cases. Arch Surg 141:765–770CrossRefPubMedGoogle Scholar
  78. 78.
    Lepage C, Rachet B, Coleman MP (2007) Survival from malignant digestive endocrine tumors in England and Wales: a population-based study. Gastroenterology 132:899–904CrossRefPubMedGoogle Scholar
  79. 79.
    Fesinmeyer MD, Austin MA, Li CI, De Roos AJ, Bowen DJ (2005) Differences in survival by histologic type of pancreatic cancer. Cancer Epidemiol Biomarkers Prev 14:1766–1773CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.University of MichiganAnn ArborUSA

Personalised recommendations